Research programme: nucleic acid therapeutics - Promosome/Unknown company

Drug Profile

Research programme: nucleic acid therapeutics - Promosome/Unknown company

Latest Information Update: 16 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Promosome; Unknown
  • Developer Promosome
  • Class DNA vaccines; Gene therapies; Nucleic acids, nucleotides, and nucleosides; RNA vaccines
  • Mechanism of Action RNA interference; RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 07 Sep 2016 mRNA engineering technologies developed at the Scripps Research Institute licensed to Promosome, world-wide, before September 2016 (Promosome website, September 2016)
  • 07 Sep 2016 Promosome and an Unknwon company enter into a collaboration for the development of nucleic acid therapeutics based on Promosome's mRNA engineering tools
  • 07 Sep 2016 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top